Insider trades
Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.
- $29.6B bought by 1412 insiders at 808 companies
- $28.4B sold by 2631 insiders outside a trading plan
- $21.2B sold by 1966 insiders under 10b5-1 plans
- 10 companies where two or more insiders bought (30 days)
Biggest buys
Past 3 months, each insider's filings added up.
-
REBNReborn CoffeeJung Jae LimCEO$23.6B
-
RSGRepublic ServicesCascade Investment, L.l.c.10% owner, +1 joint filer$1.4B
-
NMMNavios Maritime PartnersAngeliki FrangouSee Remarks$847M
-
LENLennarBerkshire Hathaway Inc.10% owner, +1 joint filer$595M
-
JEFJefferiesSumitomo Mitsui Financial Group, Inc.Director$324M
-
CRBGCorebridge FinancialLife Insurance Co Nippon10% owner$289M
-
MAIRMadison Air SolutionsErnesto Bertarelli10% owner, +1 joint filer$219M
-
GPIGroup 1 AutomotiveConifer Management, L.L.C.10% owner$187M
-
KODKodiak SciencesBaker Bros. Advisors LPDirector, +5 joint filers$157M
-
SAFXXCF GlobalEEME Energy SPV I, LLC10% owner$142M
Biggest sales
Past 3 months, each insider's filings added up. Planned sales are marked.
-
IHTInnSuites Hospitality TrustJames F WirthCEO$7.8B
-
FANGDiamondback EnergySGF FANG Holdings, LP10% owner, +1 joint filer$3.7B
-
MDLNMedlineGIC Private Ltd10% owner, +2 joint filers$1.2B
-
BIRKBirkenstockJames Michael ChuDirector$1.1B
-
CHYMChime FinancialDST Global Advisors Ltd10% owner, +9 joint filers$1.1B
-
NVDANvidiaMark A StevensDirector$947M
-
JMKEJersey Mike's SubsBlackstone Holdings II L.P.10% owner, +4 joint filers$705M
-
AURAurora InnovationUber Technologies, Inc10% owner$654M
-
ALHAlliance LaundryBdt Capital Partners, LLCDirector, +6 joint filers$590M
-
ANETArista NetworksJayshree UllalCEO$510M
Cluster buying
Companies where two or more insiders bought on the open market in the last 30 days, most buyers first
-
Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more
-
Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more
-
R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more
-
Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +2 more
-
Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more
-
John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more
-
Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more
-
Matthew G De Soto Director, Albert J. Evans Director, Kimberly J Brumbaugh Director, Theodore W Mowery Director, +1 more
-
Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO
-
Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director
MPLT insider trades
Every open-market buy and sale in MPLT, one row per filing, newest first
-
Kristopher Hanson General CounselMPLTMapLight TherapeuticsPlanned sale$193K 16,509 shares at $11.67 11% of stakeTraded Sep 16 Filed Sep 18
-
Catalyst4, Inc. 10% ownerMPLTMapLight TherapeuticsBuy$50.1M 4,400,000 shares at $11.38 +21% to stakeTraded Aug 14 Filed Aug 18
-
James Woodruff Lillie Chief Scientific OfficerMPLTMapLight TherapeuticsPlanned sale$277K 22,082 shares at $12.54 9.8% of stakeTraded Aug 3 Filed Aug 4
-
Catalyst4, Inc. 10% ownerMPLTMapLight TherapeuticsBuy$15.3M 1,209,225 shares at $12.66 +6.1% to stakeTraded Jul 28–30 Filed Jul 30
-
Troy Cox DirectorMPLTMapLight TherapeuticsBuy$149K 15,620 shares at $9.52 New stakeTraded Jul 28 Filed Jul 28
-
Jonathan Gillis CFOMPLTMapLight TherapeuticsPlanned sale$694K 18,469 shares at $37.60 11% of stakeTraded Jul 17 Filed Jul 20
-
Anatol Kreitzer Chief Discovery OfficerMPLTMapLight TherapeuticsPlanned sale$646K 17,173 shares at $37.60 8.9% of stakeTraded Jul 17 Filed Jul 20
-
Erin Pennock Foff Chief Medical OfficerMPLTMapLight TherapeuticsPlanned sale$549K 15,000 shares at $36.62 4.3% of stakeTraded Jul 15 Filed Jul 17
-
Christopher A. Kroeger CEOMPLTMapLight TherapeuticsPlanned sale$3.2M 118,235 shares at $27.19 7.8% of stakeTraded May 18 Filed May 18
-
Kristopher Hanson General CounselMPLTMapLight TherapeuticsPlanned sale$419K 13,917 shares at $30.13 7.9% of stakeTraded May 11 Filed May 11
-
Christopher A. Kroeger CEOMPLTMapLight TherapeuticsPlanned sale$1.9M 68,491 shares at $28.47 4.3% of stakeTraded May 7–11 Filed May 11
-
Erin Pennock Foff Chief Medical OfficerMPLTMapLight TherapeuticsPlanned sale$127K 4,438 shares at $28.54 1.3% of stakeTraded May 7 Filed May 11
-
James Woodruff Lillie Chief Scientific OfficerMPLTMapLight TherapeuticsPlanned sale$20K 721 shares at $28.28 0.3% of stakeTraded May 7 Filed May 11
-
Vishwas Setia CFOMPLTMapLight TherapeuticsPlanned sale$1M 36,371 shares at $28.17 9.3% of stakeTraded May 4–6 Filed May 6
-
Erin Pennock Foff Chief Medical OfficerMPLTMapLight TherapeuticsPlanned sale$1.4M 50,280 shares at $28.39 13% of stakeTraded May 4–6 Filed May 6
-
James Woodruff Lillie Chief Scientific OfficerMPLTMapLight TherapeuticsPlanned sale$1.5M 51,707 shares at $28.40 18% of stakeTraded May 4–6 Filed May 6
-
Kristopher Hanson General CounselMPLTMapLight TherapeuticsPlanned sale$388K 13,917 shares at $27.89 7.3% of stakeTraded May 4 Filed May 6
-
Christopher A. Kroeger CEOMPLTMapLight TherapeuticsPlanned sale$1.4M 49,744 shares at $28.39 3.1% of stakeTraded May 4–6 Filed May 6
-
Jonathan Gillis CAAO and PAOMPLTMapLight TherapeuticsPlanned sale$2.1M 69,835 shares at $29.89 28% of stakeTraded Apr 27–28 Filed Apr 29
-
Anatol Kreitzer Chief Discovery OfficerMPLTMapLight TherapeuticsPlanned sale$1.3M 45,422 shares at $29.66 18% of stakeTraded Apr 27 Filed Apr 29
-
Robert C. Malenka DirectorMPLTMapLight TherapeuticsPlanned sale$231K 8,593 shares at $26.90 2.6% of stakeTraded Apr 15 Filed Apr 17
-
George Pavlov DirectorMPLTMapLight TherapeuticsBuy$441K 25,000 shares at $17.65 New stakeTraded Feb 18–20 Filed Feb 20
-
Timothy John Garnett DirectorMPLTMapLight TherapeuticsBuy$253K 14,124 shares at $17.89 New stakeTraded Feb 10 Filed Feb 12
-
Novo Holdings A/S 10% ownerMPLTMapLight TherapeuticsBuy$16.2M 952,941 shares at $17.00 +35% to stakeTraded Oct 28, 2025 Filed Oct 30, 2025
-
Catalyst4, Inc. 10% ownerMPLTMapLight TherapeuticsBuy$92.5M 5,441,176 shares at $17.00 +38% to stakeTraded Oct 28, 2025 Filed Oct 29, 2025
About this data
- Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
- Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
- A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
- Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
- We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.